Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial

Cocaine-related Disorders Clinical Trial

Official title:

Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00877435
• Other study ID #: SNF-105314-120675
• Status: Completed
• Phase: N/A
• First received: April 6, 2009
• Last updated: January 28, 2015
• Start date: September 2008
• Est. completion date: October 2014

Study information

• Verified date: January 2015
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Ethikkommission
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether prize-based contingency management (prizeCM) combined with cognitive behavioral therapy (CBT) is more effective in the treatment of of cocaine-dependent patients compared to CBT only. Patients were randomized to prizeCM + CBT (experimental group) or to CBT (control group) an treated over 24 weeks. It is the first trial of this type in Europe.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 2014
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• cocaine dependence, aged 18 or older, other dependences

Exclusion Criteria:

• severe somatic, brain, or psychiatric disease, attention deficit disorders with medication methylphenidate

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cocaine-related Disorders

Intervention

Behavioral:
• Cognitive behavioral therapy (CBT)

Locations

Country	Name	City	State
Switzerland	Universitäre Psychiatrischen Kliniken	Basel
Switzerland	Fondation Phenix	Geneva

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	retention in treatment, cocaine abstinence	cocaine abstinence: at least 3 consecutive weeks of cocaine abstinence, the maximum number of weeks of continous abstinence and proportions of cocaine-free urine samples during the entire 24-week and at 6-month follow-up.	24 weeks	No
Secondary	patients' satisfaction with the therapy, clinical measures	patients' satisfaction with prize-based contingency management and with CBT	24 weeks	No

External Links

•   Psychiatric Hospital of the University of Basel - Addiction Research Unit